NASDAQ:XTLB - X T L Biopharmaceuticals Stock Price, Forecast & News

X T L Biopharmaceuticals trades on the NASDAQ under the ticker symbol "XTLB."

X T L Biopharmaceuticals's stock reverse split on the morning of Friday, February 10th 2017. The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 9th 2017. An investor that had 100 shares of X T L Biopharmaceuticals stock prior to the reverse split would have 20 shares after the split.

X T L Biopharmaceuticals Ltd (NASDAQ:XTLB) announced its quarterly earnings data on Wednesday, November, 27th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter. View X T L Biopharmaceuticals' Earnings History.

X T L Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for X T L Biopharmaceuticals.

Headlines about XTLB stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. X T L Biopharmaceuticals earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for X T L Biopharmaceuticals.

Some companies that are related to X T L Biopharmaceuticals include Zosano Pharma (ZSAN), Provectus Biopharmaceuticals (PVCT), Regulus Therapeutics (RGLS), Aerpio Pharmaceuticals (ARPO), Cellectar Biosciences (CLRB), Innovate Biopharmaceuticals (INNT), China SXT Pharmaceuticals (SXTC), Guardion Health Sciences (GHSI), Ceapro (CRPOF), Sophiris Bio (SPHS), OTCMKTS:EMBI (EMBI), Aileron Therapeutics (ALRN), OncoSec Medical (ONCS), Adial Pharmaceuticals (ADIL) and AEterna Zentaris (AEZS).

Based on aggregate information from My MarketBeat watchlists, some companies that other X T L Biopharmaceuticals investors own include Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), Akari Therapeutics (AKTX), Exelixis (EXEL), Neurocrine Biosciences (NBIX), TRACON Pharmaceuticals (TCON), T2 Biosystems (TTOO), Tetraphase Pharmaceuticals (TTPH), TherapeuticsMD (TXMD) and Vascular Biogenics (VBLT).

Shares of XTLB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XTLB stock can currently be purchased for approximately $1.30.

X T L Biopharmaceuticals has a market capitalization of $6.68 million. View Additional Information About X T L Biopharmaceuticals.

The official website for X T L Biopharmaceuticals is http://www.xtlbio.com/.

X T L Biopharmaceuticals' mailing address is 5 HACHAROSHET ST., RAANANA L3, 43656. The biopharmaceutical company can be reached via phone at 972-9955-7080 or via email at [email protected]